Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 10/20 | 0.53 |
| ▸ | CTSD | P07339 | 3/20 | 0.53 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717679 | 1.00 | ATM (0.53) | ATMBACE1CTSDBACE2KLK5 | |
| SCHEMBL5404100 | 0.89 | ATM (0.55) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL5404095 | 0.89 | ATM (0.55) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL495727 | 0.85 | ATM (0.72) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL495728 | 0.85 | ATM (0.72) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL4809494 | 0.85 | ATM (0.72) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL30318989 | 0.85 | ATM (0.72) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL22192884 | 0.85 | ATM (0.72) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL7309908 | 0.82 | KLK5 (0.65) | ATMBACE1KLK5BCHESLC6A11 | |
| SCHEMBL5223284 | 0.81 | KLK5 (0.61) | ATMBACE1KLK5BCHEPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | ATM 870/4885BACE1 3/4885CTSD 384/4885 |
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | ATM 4650/4885BACE1 2/4885CTSD 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.